Your browser doesn't support javascript.
loading
Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies.
Mallak, Nadine; Yilmaz, Burcak; Meyer, Catherine; Winters, Celeste; Mench, Anna; Jha, Abhinav K; Prasad, Vikas; Mittra, Erik.
Afiliación
  • Mallak N; Department of Diagnostic Radiology, Molecular Imaging and Therapy Section, Oregon Health & Sciences University, Portland, OR, USA.
  • Yilmaz B; Department of Diagnostic Radiology, Molecular Imaging and Therapy Section, Oregon Health & Sciences University, Portland, OR, USA.
  • Meyer C; Department of Diagnostic Radiology, Medical Physics Section, Oregon Health & Sciences University, Portland, OR, USA.
  • Winters C; Department of Diagnostic Radiology, Medical Physics Section, Oregon Health & Sciences University, Portland, OR, USA.
  • Mench A; Department of Diagnostic Radiology, Medical Physics Section, Oregon Health & Sciences University, Portland, OR, USA.
  • Jha AK; Department of Biomedical Engineering, Washington University, St. Louis, MO, USA; Department of Radiology, Mallinckrodt Institute of Radiology, Washington University, St Louis, MO, US.
  • Prasad V; Department of Radiology, Mallinckrodt Institute of Radiology, Washington University, St Louis, MO, US.
  • Mittra E; Department of Diagnostic Radiology, Molecular Imaging and Therapy Section, Oregon Health & Sciences University, Portland, OR, USA. Electronic address: mittra@ohsu.edu.
Curr Probl Cancer ; 52: 101129, 2024 Oct.
Article en En | MEDLINE | ID: mdl-39232443
ABSTRACT
Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores de Somatostatina / Tumores Neuroendocrinos / Radiofármacos Límite: Humans Idioma: En Revista: Curr Probl Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores de Somatostatina / Tumores Neuroendocrinos / Radiofármacos Límite: Humans Idioma: En Revista: Curr Probl Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos